SBT Flashcards
histamine production / degradation
histidine —-histidine decarboxylase—> histamine
degraded by INMT and diamine oxidase
role of histamine
acute inflammation + gastric acid production
4 histamine receptors
H1 - SM: CNS/endothelium/lungs/arterioles
H2 - stomach / heart
H3 - presynaptic terminals
H4 - gut / bone marrow/ basophils
what inhibits histamine release
stimulation of B2-adrenergic receptors on mast cells/basophils
EG. Salbutamol
what cells produce histamine
ECL
mast cells (activated by igE, C3a,4a,5a) - pre-made granules w/ heparin+ acidic proteins released
neurones
basophils (blood)
what effects does histamine have
dilation (H1 - vascular SM)
constriction (H1- non-vascular SM eg. lungs)
sensitises nerve endings (H1)
increases permeability of post-venues (H1)
increases HR (H2)
increased gastric production (H2)
increased exocrine secretions due to increased BF
what are H1 and H2 antagonists used for
H1 Antagonists - to treat inflammatory
(1st gen = promethazine 2/3rd gen= terfenadine /fexofenadine)
H2 antagonists - to treat gastric problems
(ranitidine/cimetidine)
bradykinin synthesis and degradation
hageman factor cleaves pre-kallikrein
kallikrein cleaves HMWkinogen –> bradykinin
broken down by kinases (ACE/carboxypeptidase etc.)
therefore ACEi = bradykinin accumulation–> drycough
effects of Bradykinin
similar to histamine
- vasodilation (dec. BP)
- constriction of non-vascular SM (bronchi/gut)
- increased permeability (exudate)
- sensitised pain endings
- arachidonic acid formation
- chemotactic to leucocytes
serotonin synthesis + degradation
l-tryptophan —” hydroxylase—-> 5-hydroxy-l-tryptophan —“decarboxylase—> 5-hydroxy-tryptophan
broken down by MAO/aldehyde dehydrogenase
arachidonic acid production
2 ways
1step pathway = phospholipids—–Phospholipase A2—>AA
2 step pathway
-phospholipids—- phospholipaseC–> DAG—DAG Ligase—>AA
-Phospholipids—phospholipase D—>phosphatidic acid—–PLA2—->AA
what known initiators stimulate AA formation
bradykinin and adrenaline
type of COX
COX 1
- active continously
- physiological roles (vascular, renal-BF, platelet aggregation, gastric protection)
COX 2
- needs to be stimulated
- inflammatory
COX 3 - variant of COX 1 (CNS pain perception)
what does COX produce from AA
TXA (platelet aggregation, vasoconstriction)
PG
- PGE2: gastric protection (by endothelial cells)
- PGD2: bronchoconstricion, decrease platelet aggregation (by mast cells)
- PGF2a: bronchoconstriction/uterine contraction
PGI2 (vasodilator, decrease platelet aggregation) endothelial cells
how are lipoxins(anti-inflammatory) and leukotrienes (inflammatory) produced
in leukocytes
5-LOX—> 5-HPETE—> 4-Leukotriene–>LTB4 (chemotaxis leucocytes) / sulphidopeptide leukotrienes (LTC,D,E4)
other lipoxygenases –> lipoxins
what 2 mediators work together during resolution stage to phagocytose/clear apoptic cells after acute inflammation
lipoxins
- recruit monocytes
- regulate activation of neutrophils
cyPG
- inhibit macrophage activation
- inhibit NF-kappabeta—> decrease inflammatory gene expression
receptors of eicosanoids
TXA—> TP receptors
sulphidopeptide leukotrienes –> cys-LT
LTB4—> BLT
prostaglandins—> DP/FP/IP/EP
why does blocking COX route worsen asthma symptoms
leukotrienes—> bronchoconstriction/oedema/mucus/vascular permeability
therefore blocking cys-LT receptors decrease effects of asthma
leyukotrine receptor antagonists = ____lukast
side effects = GI upset
poly-unsaturated fat intake effect on inflammation
decreases AA derived eicosanoids
contains DHA and EPA
DHA inhibits COX2, EPA inhibits 5-LOX
formation of anti-inflammatory mediators
what does 5-LOX require to work
FLAP
3 main effects of NSAIDS
BLOCKING COX
anti-pyretic
- IL-1B normally increases PGE2–> decreases temp sensitive neurones, lowering threshold
- decreasing PGE2
analgesic
-decreasing prostanoids that sensitise pain endings
anti-inflammatory
-decreasing PGE2/PGI2 inflammatory mediators
NSAIDs effects on bodily systems
skeletal/renal/CNS/GI/GU/cvs
skeletal
-decreases inflammatory SYMPTOMS for arthritis etc
renal
- decrease BF
- decreases Na excretion–> high BP
GI tract
- new ones are friendly (COX2 specific)
- but NSAIDs are acidic–> dec. tissue healing + GI contractions/nausea/dyspepsia (indigestion)
CNS
- overdose: paradoxical hyperpyrexia/stupor/coma
- avoid in chicken pox/influenza children—> Reye’s syndrome
Gential
- PGE2/PGF2a for uterine contraction for labour
- NSAIDs can delay labour but increase post-partum blood loss due to low TXA
resp
- despite prostanoids–> bronchoconstriction, NSAIDs have no effect on airway tone
- NSAIDs should be avoided by asthmatics as leukotriene pathway is not blocked (worsen)
- overdose aspirin–> hyperventilaiton etc.
CVS -increase bleeding time if COX1 -aspirin is beneficial as COX2 specific endothelials can regenerate new COX2 but platelets cannot COX1 (platelets not targetted)
NSAID other indications
closure of PDA
dec. alzheimers risk
ulcerative colitis
inflammation of bowel (colon + rectum) due to high PG
aminosalicylates –> 5-ASA—> decrease eicosanoids by blocking COX/LOX
what is given for gout
allopurinol (inhibits xanthine oxidase) decreasing uric acid
how glucocorticoids have an anti-inflammatory effect
block PLA2 –> decrease AA –> decreasing eicosanoids (therefore can be used by asthmatics)
they decrease inflammatory genes/ increase anti-inflammatory gene expression
block TF: AP-1 and NF-kappa beta (which normally increase inflammatory proteins)
induce Ikappabetaalpaha which blocks NF-kappabeta
side effect of corticosteroids
osteoporosis because glucocorticoids inhibit OSTEOBLASTS
gastric ulceration (dec. of COX1–> PGE2 decreased)
Cushings
lipodystrophy
cataract
methods bacteria can be resistant
- drug inactivation
- alter drug targets
- efflux pumps
- overproduction of targets
- intrinsic permeability
- metabolic by-pass